Skip to main content
S&P 5007,635.60+1.11%DOW51,799.02+0.66%NASDAQ26,398.50+1.62%BTC$76,737.00+1.83%ETH$2,467.67+4.05%GOLD$4,402.00+0.33%OIL$101.96-0.46%
Smart Investors Daily
VA

NASDAQ · VANI

Vivani Medical, Inc.

Healthcare · Medical - Devices

$1.22

Down-$0.01 (-0.41%)

Updated Sep 17, 2026, 5:49 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
82.71M
P/E ratio
-3.21
Dividend yield
0.00%
52-week range
$0.92 – $1.66
Volume
142.26K
Avg. volume
301.05K

Price performance

VANI price history

1M range · 0 trading sessions · Daily adjusted prices

VANI does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest VANI news

The latest Smart Investors Daily articles mentioning VANI.

Stock researchCompany · Overview

VANI research

Overview

Company profile and research snapshot.

Company profile

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VANI recent ratings
DateFirmRatingTarget
Jun 23, 2026Lake StreetBuy—
Mar 31, 2026HC Wainwright & Co.Buy—
Sep 2, 2025HC Wainwright & Co.Buy—
May 19, 2025HC Wainwright & Co.Buy—
Apr 16, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Vivani Medical Announces Participation in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth ConferenceSeptember 10, 2026Metropolitan ClubNew York, New YorkH.C. Wainwright 28th Annual Global

Yahoo · Aug 13, 2026

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT an

Benzinga · Aug 13, 2026

Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By